Philippines Drug Market More Than Doubles In 10 Years
This article was originally published in PharmAsia News
Executive SummaryThe Philippines' pharmaceuticals market probably has more than doubled in the past 10 years, from one worth about $976 million in 1999 to about $2.1 billion today. One of the reasons is the country remains one of the world's largest per capita buyers of medicines, equaling half of its health spending. Fewer than one-third of sales in the Philippines are generated by local drug makers, leading to drug prices two to 30 times higher for branded drugs than in surrounding Asian countries or in Canada. Generics account for 4 percent of total sales. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.